Home
Leadership
Science
- Senescence
- Diseases
Data
Media
- News
- Videos
Partners
Contact

Password Reset

Email Address

Search for:

About Us

SIWA Therapeutics, Inc. is a pre-clinical stage company with a first-in-class humanized monoclonal antibody, SIWA 318H, that selectively targets both senescent cells and cancer cells.

Recent News

In the News: SIWA Featured on Chicago Business Journal
In the News: SIWA Therapeutics Joins the Ranks of SpaceX, Apple & Google with Our Inclusion in MIT Technology Reviews Top 10 Breakthrough Technologies of 2020.
In the News: Lewis and Misty Gruber Were Interviewed by Lifespan.io

JOIN OUR MAILING LIST

Navigation

Home
Leadership
Science
- Senescence
- Diseases
Data
Media
- News
- Videos
Partners
Contact